Journal
THERAPEUTICS AND CLINICAL RISK MANAGEMENT
Volume 14, Issue -, Pages 1573-1584Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/TCRM.S146309
Keywords
CAR T-cells; tisagenlecleucel; acute lymphoblastic leukemia; CD19; cancer immunotherapy; chimeric antigen receptor
Categories
Funding
- Stand Up To Cancer St Baldrick's Pediatric Dream Team Translational Research Grant [SU2C-AACR-DT1113]
- NCI/NIH [K08 CA174750]
- NIH/NCI [P30 CA014520]
- NSF [CBET-1350178, CBET-1645123]
- NATIONAL CANCER INSTITUTE [P30CA014520, K08CA174750] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Recent advancements in immuno-oncology have resulted in the generation of novel therapies such as chimeric antigen receptor (CAR) T cells, which have revolutionized the treatment of pediatric patients with relapsed or refractory B-cell acute lymphoblastic leukemia. The journey of tisagenlecleucel (formerly CTL019) from early preclinical success to the US Food and Drug Administration approval is summarized in this review. Strategies that are currently being investigated to improve the efficacy and safety profile of CAR T-cells are also explored, as well as the factors contributing to the present state of patient access to CAR T therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
